BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 23718573)

  • 1. Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis.
    Hoofnagle JH; Van Natta ML; Kleiner DE; Clark JM; Kowdley KV; Loomba R; Neuschwander-Tetri BA; Sanyal AJ; Tonascia J;
    Aliment Pharmacol Ther; 2013 Jul; 38(2):134-43. PubMed ID: 23718573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design.
    Chalasani NP; Sanyal AJ; Kowdley KV; Robuck PR; Hoofnagle J; Kleiner DE; Unalp A; Tonascia J;
    Contemp Clin Trials; 2009 Jan; 30(1):88-96. PubMed ID: 18804555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FIB-4 as a screening and disease monitoring method in pre-fibrotic stages of metabolic dysfunction-associated fatty liver disease (MASLD).
    Albert SG; Wood EM
    J Diabetes Complications; 2024 Jul; 38(7):108777. PubMed ID: 38788522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.
    Lavine JE; Schwimmer JB; Van Natta ML; Molleston JP; Murray KF; Rosenthal P; Abrams SH; Scheimann AO; Sanyal AJ; Chalasani N; Tonascia J; Ünalp A; Clark JM; Brunt EM; Kleiner DE; Hoofnagle JH; Robuck PR;
    JAMA; 2011 Apr; 305(16):1659-68. PubMed ID: 21521847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
    Sanyal AJ; Chalasani N; Kowdley KV; McCullough A; Diehl AM; Bass NM; Neuschwander-Tetri BA; Lavine JE; Tonascia J; Unalp A; Van Natta M; Clark J; Brunt EM; Kleiner DE; Hoofnagle JH; Robuck PR;
    N Engl J Med; 2010 May; 362(18):1675-85. PubMed ID: 20427778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study.
    Bell LN; Wang J; Muralidharan S; Chalasani S; Fullenkamp AM; Wilson LA; Sanyal AJ; Kowdley KV; Neuschwander-Tetri BA; Brunt EM; McCullough AJ; Bass NM; Diehl AM; Unalp-Arida A; Chalasani N;
    Hepatology; 2012 Oct; 56(4):1311-8. PubMed ID: 22532269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis.
    Sanyal AJ; Mofrad PS; Contos MJ; Sargeant C; Luketic VA; Sterling RK; Stravitz RT; Shiffman ML; Clore J; Mills AS
    Clin Gastroenterol Hepatol; 2004 Dec; 2(12):1107-15. PubMed ID: 15625656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis.
    Said A; Akhter A
    Ann Hepatol; 2017; 16(4):538-547. PubMed ID: 28611274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin E and nonalcoholic fatty liver disease.
    Pacana T; Sanyal AJ
    Curr Opin Clin Nutr Metab Care; 2012 Nov; 15(6):641-8. PubMed ID: 23075940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
    Brunt EM; Kleiner DE; Wilson LA; Sanyal AJ; Neuschwander-Tetri BA;
    Hepatology; 2019 Aug; 70(2):522-531. PubMed ID: 30549292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
    Shyangdan D; Clar C; Ghouri N; Henderson R; Gurung T; Preiss D; Sattar N; Fraser A; Waugh N
    Health Technol Assess; 2011 Nov; 15(38):1-110. PubMed ID: 22059955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of nonalcoholic steatohepatitis: antioxidants or insulin sensitizers?
    Adams LA; Angulo P
    Clin Gastroenterol Hepatol; 2004 Dec; 2(12):1059-60. PubMed ID: 15625648
    [No Abstract]   [Full Text] [Related]  

  • 14. State of the art: treatment of nonalcoholic steatohepatitis.
    Pearlman M; Loomba R
    Curr Opin Gastroenterol; 2014 May; 30(3):223-37. PubMed ID: 24717764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of nonalcoholic fatty liver disease in children: TONIC trial design.
    Lavine JE; Schwimmer JB; Molleston JP; Scheimann AO; Murray KF; Abrams SH; Rosenthal P; Sanyal AJ; Robuck PR; Brunt EM; Unalp A; Tonascia J;
    Contemp Clin Trials; 2010 Jan; 31(1):62-70. PubMed ID: 19761871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
    Sato K; Gosho M; Yamamoto T; Kobayashi Y; Ishii N; Ohashi T; Nakade Y; Ito K; Fukuzawa Y; Yoneda M
    Nutrition; 2015; 31(7-8):923-30. PubMed ID: 26059365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
    Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
    Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis.
    Boettcher E; Csako G; Pucino F; Wesley R; Loomba R
    Aliment Pharmacol Ther; 2012 Jan; 35(1):66-75. PubMed ID: 22050199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial.
    Panahi Y; Ghamarchehreh ME; Beiraghdar F; Zare R; Jalalian HR; Sahebkar A
    Hepatogastroenterology; 2012 Oct; 59(119):2099-2103. PubMed ID: 23234816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.
    Corey KE; Rinella ME
    Dig Dis Sci; 2016 May; 61(5):1387-97. PubMed ID: 26942734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.